The sealed bottles were supposed to contain 30 Montelukast sodium tablets, but instead contained 90 Losartan potassium tablets. Montelukast is used to control allergy and asthma symptoms, whereas Losartan is used to control high blood pressure.
The tablet mix-up could cause renal dysfunction, elevated potassium level and low blood pressure.
“This risk is especially high for pregnant women taking the allergy and asthma medication Montelukast because Losartan, which is indicated to treat high blood pressure, could harm or kill the fetus,” the FDA warned.
The affected lot number is MON17384, which has an expiration date of Dec. 31, 2019.
More articles on pharmacy:
Blood pressure drug recalled after labeling mix-up
Narcan maker to be acquired by Emergent Biosolutions for $735M
US-Mexico trade deal grants drugmakers 10 years of patent exclusivity on biologics
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
